Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination regimen of three drugs—cyclophosphamide, methylprednisolone, and prednisone—used primarily as an immunosuppressive and anti-inflammatory therapy in severe autoimmune diseases such as lupus nephritis and systemic vasculitis. Cyclophosphamide is an alkylating agent that suppresses the immune system by cross-linking DNA, leading to cell death in rapidly dividing cells including lymphocytes. Methylprednisolone and prednisone are synthetic glucocorticoid corticosteroids that reduce inflammation by inhibiting leukocyte migration and suppressing immune responses. This combination aims to maximize immunosuppression for disease control while balancing toxicity risks[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclophosphamide + methylprednisolone + prednisone.